A Phase 1/2 interventional study of Sunvozertinib in Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Active, not recruiting at 124 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 12 under way, 2 of them phase 3. sunvozertinib · Carcinoma, Non-Small-Cell Lung.
Among the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, reaches primary completion later than 1 of the 11 other live ones, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
sunvozertinib: first FDA approval 2025 (ZEGFROVY). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 2
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 315 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 100 across the 13 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 8 most frequent:
Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals: 6 open now, 9 under way, 2 of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 2nd registered.
Dizal Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2018.
3 of the studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05559645Peking Union Medical College HospitalAssessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) | 2026-12-31 |
| NCT07117890Fudan UniversitySunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations | 2027-02-20 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Dizal Pharmaceuticals’s 12 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of Sunvozertinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation, dose expansion, food effect (Part A) and dose extension (Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A Dose expansion: Dose expansion cohort 5: NSCLC patients with EGFR Exon20ins, who have not received prior systemic therapy (treatment naïve).
Part B Dose extension:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sunvozertinib
Drug: Sunvozertinib
Drug: Sunvozertinib
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
Drug: Sunvozertinib
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
Drug: Sunvozertinib
Patients with EGFR Exon20ins, treatment naïve
Drug: Sunvozertinib
Drug: Sunvozertinib
Patients with EGFR Exon20ins
Drug: Sunvozertinib
Patients with EGFR Exon20ins
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Also known as: DZD9008
Part A Dose Escalation: Dose Limiting Toxicities (DLTs).
To evaluate the safety and tolerability and defined the maximum tolerated dose (MTD) of sunvozertinib. DLT was evaluated in the DLT observation frame.
Time frame: The DLT observation period is defined as the 28 days after the first multiple dose (up to 36 days from baseline).
Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).
To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).
Time frame: through the study completion, an average of around 1 year for part B
Part B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1
To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.
Time frame: Through the study completion, an average of around 1 year for part B
Part B: DoR, PFS According to RECIST 1.1 Using Assessments Performed by an IRC; DoR, PFS Using Investigators Assessments According to RECIST 1.1
To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.
Time frame: Through the study completion, an average of around 1 year for part B
Part B: AEs/SAEs
To determine the safety and tolerability of Sunvozertinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.
Time frame: Through the study completion, an average of around 1 year for part B
Part A: Confirmed ORR and DCR by Investigator.
To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. Confirmed ORR was defined as the percentage of patients achieving a CR (Complete Response) or PR (Partial Response) and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by a subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.
Time frame: The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.
Part A: DoR and PFS by Investigator.
To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. DoR was presented for patients with confirmed objective response (CR or PR). DoR was the time from date of first documentation of CR or PR, which was subsequently confirmed, to date of first documentation of objective progression or death. Patients who had no documentation of objective progression or death was censored. PFS was the time from first dose date of sunvozertinib to date of first documentation of progression or death due to any cause, whichever occurred first. Patient who had no PFS event was censored.
Time frame: The maximum median of DoR was 19.3 months, and the maximum median of PFS was 12.5 months for part A.
Part A: Confirmed ORR and DCR by Independent Review Committee (IRC).
To retrospectively assess anti-tumor activity of sunvozertinib in treatment-naive NSCLC patients with EGFR Exon20ins according to RECIST 1.1 by IRC. Confirmed ORR was defined as the percentage of patients achieving a CR or PR and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.
Time frame: The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.
Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008
Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the single dose.
Time frame: Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)
Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
Time frame: Cycle 0 Day 1: 0 (predose) up to 168 hours (for Part A escalation); Cycle 1 Day 1: 0 (predose) up to 24 hours (for Part A expansion)
Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008
Maximum observed plasma concentration(ng/mL), at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.
Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose expansion and expansion)
Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008
Area under the plasma concentration-time curve in the dose interval at steady state, calculated by the linear up/log down rule.
Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose escalation and expansion)
Part A Food Effect: Maximum Plasma Concentration (Cmax) of DZD9008
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose, in the fasted or fed state.
Time frame: Day 1 and Day 9: 0 (predose) up to 168 hours.
Part A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008
Area under the plasma concentration-time-curve from time zero the last quantifiable time point, calculated by the linear up/log down rule, in the fasted or fed state.
Time frame: Day 1 and Day 9: 0 (predose) up to 168 hours.
Part B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.
Time frame: Cycle 1 Day 1: 0 (predose) up to 24 hours
Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753.
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
Time frame: Cycle 1 Day 1: 0 (predose) up to 24 hours
Part B: Cmax,ss, at Steady State of DZD9008 and DZ0753
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.
Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours
Part B: AUCss, at Steady State of DZD9008 and DZ0753.
Area under the plasma concentration-time curve from time zero in the dose interval at steady state, calculated by the linear up/log down rule.
Time frame: Cycle 2 Day 1: 0 (predose) up to 24 hours
| Milestone | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 3 | 7 | 6 | 10 | 14 | 14 | 7 | 31 | 0 | 5 | 7 | 91 | 111 |
| Completed | 3 | 5 | 3 | 5 | 5 | 5 | 8 | 10 | 3 | 24 | 0 | 4 | 6 | 54 | 61 |
| Not completed | 0 | 1 | 0 | 2 | 1 | 5 | 6 | 4 | 4 | 7 | 0 | 1 | 1 | 37 | 50 |
| Withdrew: Death | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 1 | 4 | 0 | 0 | 0 | 33 | 40 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 2 | 2 | 3 | 0 | 1 | 0 | 3 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Site terminated by sponsor or non compliance | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
To evaluate the safety and tolerability and defined the maximum tolerated dose (MTD) of sunvozertinib. DLT was evaluated in the DLT observation frame.
| Participants | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg |
|---|---|---|---|---|---|
| Part A Dose Escalation: Dose Limiting Toxicities (DLTs). | 0 | 0 | 0 | 1 | 1 |
To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).
| percentage of participants | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC). | 45.9 (33.6 to 58.5) | 45.8 (34.8 to 57.0) |
To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.
| percentage of participants | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| confirmed DCR by IRC | 89.4 (80.8 to 95.0) | 88.8 (81.2 to 94.1) |
| confirmed DCR by investigator | 88.2 (79.4 to 94.2) | 88.8 (81.2 to 94.1) |
To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.
| months | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Median duration of response (IRC) | NA (7.2 to NA) | NA (6.7 to NA) |
| Median duration of response (investigator) | 8.3 (7.0 to NA) | 8.8 (5.3 to 18.0) |
| Median progression free survival (IRC) | 8.4 (6.8 to 11.2) | 6.9 (5.6 to 11.0) |
| Median progression free survival (investigator) | 8.3 (5.5 to 10.9) | 6.8 (5.5 to 8.3) |
To determine the safety and tolerability of Sunvozertinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.
| participants | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Any TEAE | 91 | 111 |
| Any treatment- emergent SAE | 37 | 41 |
To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. Confirmed ORR was defined as the percentage of patients achieving a CR (Complete Response) or PR (Partial Response) and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by a subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.
| percentage of participants | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Confirmed objective response rate | 0 (0.0 to 70.8) | 16.7 (0.4 to 64.1) | 0 (0.0 to 70.8) | 42.9 (9.9 to 81.6) | 0 (0.0 to 52.2) | 50 (18.7 to 81.3) | 30.8 (9.1 to 61.4) | 21.4 (4.7 to 50.8) | 40.0 (5.3 to 85.3) | 55.2 (35.7 to 73.6) | — | 20.0 (0.5 to 71.6) | 14.3 (0.4 to 57.9) |
| Confirmed disease control rate | 100.0 (29.2 to 100.0) | 50.0 (11.8 to 88.2) | 66.7 (9.4 to 99.2) | 71.4 (29.0 to 96.3) | 60.0 (14.7 to 94.7) | 80 (44.4 to 97.5) | 84.6 (54.6 to 98.1) | 92.9 (66.1 to 99.8) | 80.0 (28.4 to 99.5) | 93.1 (77.2 to 99.2) | — | 60.0 (14.7 to 94.7) | 85.7 (42.1 to 99.6) |
To assess preliminary anti-tumor activity of sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator. DoR was presented for patients with confirmed objective response (CR or PR). DoR was the time from date of first documentation of CR or PR, which was subsequently confirmed, to date of first documentation of objective progression or death. Patients who had no documentation of objective progression or death was censored. PFS was the time from first dose date of sunvozertinib to date of first documentation of progression or death due to any cause, whichever occurred first. Patient who had no PFS event was censored.
| month | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median duration of response(month) | NA (NA to NA) | 4.0 (NA to NA) | NA (NA to NA) | 5.5 (2.8 to 5.5) | NA (NA to NA) | NA (3.2 to NA) | 4.2 (3.2 to NA) | 6.3 (2.8 to 23.4) | 4.3 (3.0 to 5.6) | 9.8 (5.6 to NA) | — | 19.3 (NA to NA) | 5.6 (NA to NA) |
| Median progression free survival(month) | 3.1 (3.1 to 9.6) | 1.9 (0.9 to 22.5) | 12.5 (1.7 to NA) | 3.3 (1.2 to 7.4) | 4.6 (1.0 to 6.0) | 4.9 (1.2 to NA) | 5.5 (4.0 to 12.7) | 4.2 (2.4 to 9.0) | 4.2 (1.4 to NA) | 10.8 (5.5 to 12.5) | — | 3.3 (1.4 to 21.3) | 5.3 (3.2 to NA) |
To retrospectively assess anti-tumor activity of sunvozertinib in treatment-naive NSCLC patients with EGFR Exon20ins according to RECIST 1.1 by IRC. Confirmed ORR was defined as the percentage of patients achieving a CR or PR and was confirmed by subsequent tumor assessment at least 4 weeks within the study period. Confirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by subsequent tumor assessment at least 4 weeks within the study period. Patients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.
| percentage of participants | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal |
|---|---|
| Confirmed objective response rate | 62.1 (42.3 to 79.3) |
| Confirmed disease control rate | 89.7 (72.6 to 97.8) |
Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the single dose.
| ng/mL | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008 | 38.95 ± 37.3 | 89.19 ± 53.5 | NA ± NA | 428.8 ± 69.2 | 167.8 ± 90.7 | 176.3 ± 50.7 | 286.7 ± 62.6 | 253.0 ± 44.1 | 346.5 ± 33.5 | 354.3 ± 68.3 | — |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
| h*ng/mL | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 | 1434 ± 45.9 | 2693 ± 115.8 | NA ± NA | 12540 ± 69.7 | 6419 ± 60.0 | 2300 ± 46.0 | 3800 ± 56.9 | 3313 ± 39.3 | 4517 ± 28.2 | 4338 ± 60.3 | — |
Maximum observed plasma concentration(ng/mL), at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.
| ng/mL | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008 | 82.85 ± 17.2 | 229.4 ± 50.6 | NA ± NA | 590.2 ± 80.9 | 677.0 ± 21.9 | 358.0 ± 53.4 | 717.5 ± 40.9 | 613.3 ± 48.8 | 819.3 ± 57.3 | 716.5 ± 41.7 | — |
Area under the plasma concentration-time curve in the dose interval at steady state, calculated by the linear up/log down rule.
| h*ng/mL | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008 | 1506 ± 13.2 | 3823 ± 55.6 | NA ± NA | 10240 ± 78.1 | 12030 ± 25.2 | 5906 ± 52.3 | 11630 ± 40.3 | 9949 ± 45.8 | 14170 ± 47.9 | 12030 ± 40.2 | — |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose, in the fasted or fed state.
| ng/mL | Part A Food Effect Cohort: Sunvozertinib 300 mg |
|---|---|
| Part A Food effect: Maximum Plasma Concentration (Cmax) of DZD9008 under Fasted condition | 307.0 ± 59.6 |
| Part A Food effect: Maximum Plasma Concentration (Cmax) of DZD9008 under High-Fat Meal condition | 331.6 ± 48.8 |
Area under the plasma concentration-time-curve from time zero the last quantifiable time point, calculated by the linear up/log down rule, in the fasted or fed state.
| h*ng/mL | Part A Food Effect Cohort: Sunvozertinib 300 mg |
|---|---|
| Part A Food effect: AUC0-t of DZD9008 under Fasted condition | 8266 ± 65.8 |
| Part A Food effect: AUC0-t of DZD9008 under High-Fat Meal condition | 10050 ± 67.5 |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.
| ng/mL | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Part B: Maximum Plasma Concentration (Cmax) of DZD9008 | 173.4 ± 80.4 | 325.8 ± 73.7 |
| Part B: Maximum Plasma Concentration (Cmax) of DZ0753 | 18.90 ± 113.4 | 40.40 ± 78.2 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
| h*ng/mL | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Part B: AUC0-t of DZD9008 | 2423 ± 71.9 | 4397 ± 55.7 |
| Part B: AUC0-t of DZ0753 | 200.4 ± 125.2 | 448.5 ± 69.9 |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.
| ng/mL | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Part B: Maximum Plasma Concentration (Cmax,ss) of DZD9008 | 342.8 ± 57.4 | 642.3 ± 48.1 |
| Part B: Maximum Plasma Concentration (Cmax,ss) of DZ0753 | 42.58 ± 108.0 | 112.4 ± 83.7 |
Area under the plasma concentration-time curve from time zero in the dose interval at steady state, calculated by the linear up/log down rule.
| h*ng/mL | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|
| Part B: AUCss, at Steady State of DZD9008 | 6286 ± 56.1 | 10230 ± 47.5 |
| Part B: AUCss, at Steady State of DZ0753 | 728.9 ± 112.2 | 1722 ± 84.9 |
Collected over Survival data continued to be collected for Part B participants following treatment discontinuation. SAEs and other AEs were monitored from the study treatment until the end of treatment, an average of approximately 11 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | 2/7 (28.6%) | 4/7 (57.1%) | 7/7 (100%) |
| Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | 1/10 (10%) | 4/10 (40%) | 10/10 (100%) |
| Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | 0/14 (0%) | 5/14 (35.7%) | 14/14 (100%) |
| Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | 2/14 (14.3%) | 9/14 (64.3%) | 14/14 (100%) |
| Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | 4/31 (12.9%) | 14/31 (45.2%) | 31/31 (100%) |
| Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | — | — | — |
| Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | 33/91 (36.3%) | 37/91 (40.7%) | 91/91 (100%) |
| Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg | 40/111 (36%) | 41/111 (36.9%) | 111/111 (100%) |
| Event | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/3 | 0/6 | 1/3 | 2/7 | 1/6 | 0/10 | 1/14 | 1/14 | 0/7 | 1/31 | — | 0/5 | 0/7 | 6/91 | 6/111 |
| DysarthriaNervous system disorders | 0/3 | 0/6 | 1/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| Aortic valve stenosisCardiac disorders | 0/3 | 1/6 | 0/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| ArrhythmiaCardiac disorders | 0/3 | 0/6 | 0/3 | 0/7 | 1/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| DeathGeneral disorders | 0/3 | 1/6 | 0/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| Generalised oedemaGeneral disorders | 0/3 | 0/6 | 0/3 | 0/7 | 1/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/3 | 0/6 | 0/3 | 1/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| TachycardiaCardiac disorders | 0/3 | 0/6 | 0/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 0/31 | — | 0/5 | 1/7 | 0/91 | 0/111 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/6 | 0/3 | 1/7 | 0/6 | 0/10 | 0/14 | 0/14 | 0/7 | 1/31 | — | 0/5 | 0/7 | 0/91 | 9/111 |
| Pancreatic enzyme abnormalityGastrointestinal disorders | 0/3 | 0/6 | 0/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 1/7 | 0/31 | — | 0/5 | 0/7 | 0/91 | 0/111 |
| Event | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/3 | 2/6 | 2/3 | 4/7 | 5/6 | 7/10 | 12/14 | 12/14 | 7/7 | 25/31 | — | 3/5 | 5/7 | 65/91 | 94/111 |
| VomitingGastrointestinal disorders | 0/3 | 0/6 | 1/3 | 3/7 | 5/6 | 1/10 | 6/14 | 3/14 | 1/7 | 7/31 | — | 0/5 | 1/7 | 32/91 | 49/111 |
| NauseaGastrointestinal disorders | 0/3 | 1/6 | 0/3 | 2/7 | 3/6 | 2/10 | 7/14 | 6/14 | 3/7 | 5/31 | — | 4/5 | 4/7 | 28/91 | 48/111 |
| ConstipationGastrointestinal disorders | 0/3 | 2/6 | 2/3 | 2/7 | 1/6 | 2/10 | 2/14 | 5/14 | 2/7 | 7/31 | — | 1/5 | 0/7 | 25/91 | 16/111 |
| FatigueGeneral disorders | 2/3 | 1/6 | 1/3 | 0/7 | 3/6 | 0/10 | 3/14 | 6/14 | 1/7 | 5/31 | — | 2/5 | 3/7 | 24/91 | 22/111 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/3 | 0/6 | 0/3 | 0/7 | 0/6 | 0/10 | 0/14 | 0/14 | 1/7 | 4/31 | — | 0/5 | 1/7 | 8/91 | 6/111 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/3 | 0/6 | 2/3 | 3/7 | 1/6 | 0/10 | 3/14 | 2/14 | 2/7 | 7/31 | — | 0/5 | 2/7 | 7/91 | 8/111 |
| RashSkin and subcutaneous tissue disorders | 2/3 | 1/6 | 0/3 | 0/7 | 3/6 | 1/10 | 4/14 | 6/14 | 1/7 | 16/31 | — | 1/5 | 0/7 | 34/91 | 52/111 |
| StomatitisGastrointestinal disorders | 0/3 | 0/6 | 1/3 | 0/7 | 0/6 | 2/10 | 1/14 | 4/14 | 4/7 | 10/31 | — | 0/5 | 0/7 | 18/91 | 22/111 |
| PyrexiaGeneral disorders | 0/3 | 0/6 | 0/3 | 1/7 | 0/6 | 3/10 | 2/14 | 0/14 | 4/7 | 0/31 | — | 0/5 | 0/7 | 7/91 | 8/111 |
No patient was enrolled in Part A dose expansion cohort 6 due to conflict with enrollment of Part B.
| Age, Continuous(years) | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 48.0 (38 to 72) | 62.0 (48 to 83) | 57.0 (55 to 74) | 64.0 (57 to 82) | 63.5 (48 to 85) | 61 (41 to 83) | 62.5 (41 to 76) | 60.5 (34 to 73) | 64 (38 to 73) | 61 (37 to 96) | — | 44.0 (39 to 82) | 65.0 (55 to 78) | 62 (35 to 88) | 64 (37 to 89) | 62.0 (34 to 96) |
| Sex: Female, Male(Participants) | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 2 | 3 | 4 | 7 | 6 | 9 | 2 | 13 | 0 | 4 | 6 | 61 | 63 | 186 |
| Male | 0 | 3 | 1 | 4 | 2 | 3 | 8 | 5 | 5 | 18 | 0 | 1 | 1 | 30 | 48 | 129 |
| Race (NIH/OMB)(Participants) | Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg | Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg | Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg | Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg | Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg | Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State | Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal | Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg | Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted | Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 5 | 2 | 5 | 3 | 10 | 9 | 13 | 7 | 23 | 0 | 1 | 0 | 59 | 65 | 204 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 3 |
| White | 1 | 1 | 1 | 2 | 3 | 0 | 5 | 1 | 0 | 5 | 0 | 4 | 6 | 30 | 44 | 103 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | 0 | 5 |
Showing the first 100 of 124 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jul 2024, 60 months.
Results were first posted in Dec 2025, 1 year 4 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 60 months is close to that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sunvozertinib
Carcinoma, Non-Small-Cell Lung →